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A peptide corresponding to the neuropilin-1-binding site on
VEGF165 induces apoptosis of neuropilin-1-expressing breast
tumour cells
MP Barr1,4, AM Byrne1,4, AM Duffy1, CM Condron1, M Devocelle2, P Harriott2,3, DJ Bouchier-Hayes1 and
JH Harmey*,1
1Department of Surgery, Royal College of Surgeons in Ireland, Education & Research Centre, Beaumont Hospital, Dublin 9, Ireland; 2Centre for Synthesis
& Chemical Biology, Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, St Stephen’s Green, Dublin 2, Ireland;
3School of Biology and Biochemistry, Medical Biology Centre, Queen’s University of Belfast, Northern Ireland
There is increasing evidence that vascular endothelial growth factor (VEGF) has autocrine as well as paracrine functions in tumour
biology. Vascular endothelial growth factor-mediated cell survival signalling occurs via the classical tyrosine kinase receptors Flt-1,
KDR/Flk-1 and the more novel neuropilin (NP) receptors, NP-1 and NP-2. A 24-mer peptide, which binds to neuropilin-1, induced
apoptosis of murine and human breast carcinoma cells, whereas a peptide directed against KDR had no effect. Both anti-NP1 and
anti-KDR peptides induced endothelial cell apoptosis. Confocal microscopy using 5-(6)-carboxyfluorescein-labelled peptides showed
that anti-NP1 bound to both tumour and endothelial cells, whereas anti-KDR bound endothelial cells only. This study demonstrates
that NP-1 plays an essential role in autocrine antiapoptotic signalling by VEGF in tumour cells and that NP1-blockade induces tumour
cell and endothelial cell apoptosis. Specific peptides can therefore be used to target both autocrine (tumour cells) and paracrine
(endothelial cells) signalling by VEGF.
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Angiogenesis, the growth of new capillaries, is a critical process in
tumour growth and metastasis (Folkman, 1995). Numerous
angiogenic factors have been identified to date, the most potent
of these being vascular endothelial growth factor (VEGF),
otherwise known as vascular permeability factor (VPF). Anti-
VEGF strategies have been shown to potently inhibit tumour
growth and metastasis (Kim et al, 1993; Millauer et al, 1996; Yuan
et al, 1996; Xu et al, 2000).
In endothelial cells, the biological activities of VEGF are
mediated through its binding to two high-affinity tyrosine kinase
receptors, Flt-1 (VEGFR-1), KDR (VEGFR-2) and its murine
homologue, Flk-1 (Waltenberger et al, 1994). At least five isoforms
of VEGF are produced as a result of alternative mRNA splicing,
where these isoforms differ with regard to the expression of exons
6 and 7 of the VEGF gene. More recently, neuropilin-1 (NP-1) has
been identified as an isoform-specific receptor for VEGF (Soker
et al, 1996; Gagnon et al, 2000). Originally identified as a receptor
for the semaphorin/collapsin family of neuronal guidance media-
tors (Fujisawa and Kitsukawa, 1998), NP-1 is expressed on
endothelial cells and is also found on the cell surface of several
tumour cells such as breast, prostate and melanoma cells. Despite a
similar domain structure, NP-1 shares approximately 44% amino-
acid homology with neuropilin-2 (NP-2). The NP-1-binding site in
VEGF165 is encoded by VEGF exon 7, which is absent in the VEGF
isoforms VEGF121 and VEGF145 (Soker et al, 1997). The related NP-
2 receptor also behaves as a splice form-specific VEGF receptor
that also binds VEGF165. Unike NP-1, NP-2 binds VEGF145
(Gluzman-Poltorak et al, 2000). Neither receptor binds VEGF121,
which lacks the exon 7 domain.
As neuropilins lack an intracellular tyrosine kinase domain, they
may act in conjunction with other cell surface receptors in order to
mediate cell signalling. It has been reported that neuropilin
receptors can form complexes with members of the plexin family,
where the plexin is the signal transducing element of this
neuropilin/plexin complex (Tamagnone et al, 1999; Rohm et al,
2000). Plexin-A1 and plexin-A2 form complexes with the
neuropilins. This complex formation does not depend on the
presence of semaphorin (Takahashi and Strittmatter, 2001).
Until recently, VEGF produced by tumour cells and stromal cells
such as macrophages was thought to act in a paracrine manner
stimulating endothelial cell growth and differentiation. However,
VEGF was recently shown to be an autocrine factor for breast
carcinoma invasion in vitro (Bachelder et al, 2002). We and others
have also demonstrated that VEGF acts in an autocrine fashion
(Bachelder et al, 2001; Pidgeon et al, 2001). Furthermore, we
demonstrated that VEGF-neutralising antibodies induced apoptosis
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of murine 4T1 and human MDA-MB-231 mammary adenocarci-
noma cells. In the present study, we examined VEGF receptor
expression and the effect of peptides targeting Flk-1/KDR and
NP-1 on apoptosis of 4T1 and MDA-MB-231 breast carcinoma cells.
MATERIALS AND METHODS
Cell culture
The murine mammary adenocarcinoma 4T1 cell line was
generously provided by Dr Fred Miller (Duke University, USA).
The MDA-MB-231 human mammary adenocarcinoma cell line was
purchased from the American Tissue Culture Collection (ATCC).
4T1 tumour cells were maintained in RPMI 1640 medium in a
humidified atmosphere of 5% CO2 in air at 371C. MDA-MB-231
cells were maintained in sealed flasks with L-15 medium at 371C.
The RENCA cell line (murine renal cell carcinoma), a gift from
IJ Fidler, MD Anderson Cancer Centre, USA, were grown in
MEM medium supplemented with nonessential amino acids (1 ),
L-glutamine (200 mM) and sodium pyruvate (100 mM). All media
were supplemented with 10% heat-inactivated fetal calf serum,
penicillin (100 U ml1) and streptomycin (100 mg ml1) (Gibco-
BRL, Paisley, UK). Primary human umbilical vein endothelial cells
(HUVEC), a gift from Ambrose Clarke, Department of Clinical
Pharmacology, RCSI, were cultured in M-199 culture medium
supplemented with 20% fetal calf serum, endothelial cell growth
mitogen (Sigma, Ireland), penicillin (100 U ml1) and strepto-
mycin (100mg ml1). All cells were maintained as monolayer
cultures, and exponentially growing cultures were used for
experiments.
Western immunoblotting
Cells were lysed for 1 h on ice in 1 ml of lysis buffer (5 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% Triton –X-100, 0.5%
SDS, 0.5% deoxycholic acid, 1 mM phenylmethylsulphonyl fluor-
ide). Total protein concentration was determined using the
Bicinchoninic Acid assay according to the manufacturer’s instruc-
tions (Pierce, IL, USA).
In total, 30 mg of total protein was separated on an 8%
denaturing polyacrylamide gel and transferred to nitrocellulose
membranes. Membranes were blocked with 5% nonfat dry milk in
Tris-buffered saline (25 mM Tris-HCl, pH 7.6, 150 mM NaCl)
containing 0.1% Tween-20 (TBST) for 1 h at room temperature
and incubated for 60 min with NP-1 antibody (Santa Cruz Biotech,
CA, USA), diluted 1 : 100 in 5% nonfat dry milk in TBST. Blots
were stripped and reprobed with NP-2 antibody (Upstate
Biotechnology, NY, USA), diluted 1 : 500 under similar conditions
as that used for NP-1. Following six 5 min washes in TBST,
membranes were incubated for 90 min with horseradish per-
oxidase-conjugated goat anti-rabbit antibody (DAKO, Glostrup,
Denmark), diluted 1 : 2000 in TBST. Blots were probed using
anti-Flt-1 and anti-Flk-1/KDR antibodies (R&D Systems, UK) at a
concentration of 0.20 mg ml1 and using a HRP-conjugated mouse
anti-goat antibody, 1 : 2000. Bound antibody was detected using
enhanced chemiluminescence (Pierce, IL, USA).
Peptide synthesis and purification
A 24-mer anti-NP1 VEGF peptide corresponding to exon 7 of
VEGF165, CSCKNTDSRCKARQLELNERTCRC-NH2 (Soker et al,
1997), a corresponding ‘scrambled’ control peptide, NCTES-
KARCRLCSRCNDELTRKCQ-NH2, and a 7-mer anti-KDR/Flk-1
peptide, ATWLPPR-OH (Binetruy-Tournaire et al, 2000) were
synthesised using an automated 433A peptide synthesizer (Applied
Biosystems Inc., USA). Chromatographic analysis and purification
were performed using a BioCAD SPRINT Perfusion Chromato-
graphy workstation (PerSeptive Biosystems) using POROS 20R2
Reversed Phase Perfusion Chromatography packing for analysis or
a Jupiter Column (Phenomenex) for purification. For character-
isation of peptides, Matrix Assisted Laser Desorption Ionisation-
Time of Flight (MALDI-TOF) mass spectrometry was used.
Confocal microscopy
MDA-MB-231, 4T1 and HUVEC cells were grown on glass chamber
slides (Becton Dickinson, UK) and treated with 5(6)-carboxyfluor-
escein labelled anti-NP1 and anti-KDR peptides for 18 h. Slides
were washed four times in TBS and mounted in fluorescent
mounting medium (DAKO, Glostrup, Denmark). Peptide binding
was examined using a Zeiss LSM 510 laser scanning confocal
microscope (Carl Zeiss International, Germany). The objective
used was a PLAN-NEOFLUAR 40 /1.3 oil DIC objective.
Flow cytometry analysis
Cells (5 104) were seeded in six-well culture plates and treated for
24 h with VEGF control (125 mg ml1), anti-NP1 (125mg ml1) and
anti-KDR (210 mg ml1) peptides in medium containing 1% FCS.
Cells were washed in 1 PBS containing 2% BSA and apoptosis
was assessed using the TACSt Annexin V-FITC/PI apoptosis
detection kit (R&D Systems, UK) according to the manufacturer’s
instructions. Flow cytometric analysis was performed using the
FACSCalibur analysis system (Becton Dickinson, CA, USA).
Apoptosis was measured as a percentage of the total number of
cells and expressed as a percentage of controls in three
independent experiments.
Hoechst staining of apoptotic cells
Nuclear staining of apoptotic tumour cells was examined by
Hoechst staining (Singhal et al, 1999). Cells were treated with
blocking peptides, as before, for 24 h. At the end of the incubation
period, cells were washed in PBS and pelleted by centrifugation at
1500 r.p.m. for 5 min. Cells (1 105) were resuspended in 100%
methanol containing Hoechst 33342 (Sigma-Aldrich, Ireland) at a
final concentration of 1 mg ml1 and incubated at 371C for 10 min.
Cytospins were prepared, mounted in fluorescent mounting
medium (DAKO, Glostrup, Denmark) and viewed by UV light
microscopy (Nikon, Melville, USA).
Statistical analysis
Statistical comparison between groups was carried out using
analysis of variance (ANOVA) with LSD post hoc correction, using
the SPSSt statistical software package (SPSS Inc., IL, USA). Data
were expressed as mean7standard error of the mean (s.e.m) and
taken as significant where Po0.05.
RESULTS
Tumour cell expression of VEGF receptors
Vascular endothelial growth factor is constitutively expressed by
murine 4T1 and human MDA-MB-231 tumour cells (4T1, 59.107
1.87 pg VEGF permg protein; MDA-MB-231, 20.5671.51 pg VEGF
per mg protein, Pidgeon et al, 2001). In the present study, we
examined the effect of blocking the binding of VEGF to the NP-1
and KDR receptors using a peptide-based approach. Western blot
analysis identified NP-1 and NP-2 receptors as a 130 and 135 kDa
protein, respectively, in 4T1 (NP-1), MDA-MB-231 (NP-1 and NP-
2) and HUVEC (NP-1 and NP-2) cells (Figure 1A), but both were
absent in the RENCA cell line (Figure 1B). Of the tumour cell lines
examined, we identified the expression of Flt-1 in 4T1, RENCA and
HUVEC cells only. To date, we have been unable to detect Flk-1/
KDR in 4T1 and MDA-MB-231 tumour cells using immuno-
cytochemistry and Western blotting.
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Anti-NP1 peptides bind to tumour and endothelial cells,
while anti-KDR peptides bind to endothelial cells only
We examined the binding of anti-NP1 and anti-KDR peptides
labelled with 5(6)-carboxyfluorescein to tumour and endothelial
cells by confocal microscopy. The anti-NP1 peptide bound to 4T1
(Figure 2A), MDA-MB-231 (Figure 2B) and HUVEC (Figure 2C)
cells. In contrast, the anti-KDR peptide did not bind to murine 4T1
and human MDA-MB-231 tumour cells but did bind to HUVEC
cells, where these are known to express functional KDR.
Vascular endothelial growth factor receptor blockade
induces apoptosis of tumour and endothelial cells
The anti-KDR peptide, ATWLPPR, was previously identified from
a phage-display library and shown to block the KDR receptor,
inducing apoptosis of endothelial cells (Binetruy-Tournaire et al,
2000). We also synthesised a 24-mer anti-NP1 peptide correspon-
ding to exon 7 of VEGF165 (Soker et al, 1997) as the NP-1-binding
motif has been shown to reside within exon 7 of this VEGF
isoform. Having demonstrated that murine 4T1 and human MDA-
MB-231 tumour cells express NP-1 and endothelial cells (HU-
VEC’s) express both NP-1 and KDR, we studied the effect of anti-
NP1 and anti-KDR peptides on apoptosis. HUVECs were used as a
positive control as these are known to express Flt-1, KDR and NP-1
(Peters et al, 1993). Treatment with NP-1-blocking peptide resulted
in a significant increase in apoptosis of both tumour cells
and endothelial cells (4T1, 226.72738.80%; MDA-MB-231,
126.99714.49%; HUVECs, 196.77729.51%, Po0.05) relative to
cells treated with a scrambled control peptide (4T1, 88.66722.77%;
MDA-MB-231, 71.4577.32%; HUVECs, 83.4078.78%, po0.05,
Figure 3A, B and C, respectively). Anti-KDR peptide induced
significant apoptosis of HUVECs relative to controls (14177% vs
control, Po0.05) but had no effect on tumour cell apoptosis in
murine and human tumour cells (4T1, 77.12720.82%; MDA-MB-
231, 86.2475.61% vs control), consistent with the lack of expression
of Flk-1/KDR in these cells. Representative dot plots showing
induction of tumour cell (4T1) and endothelial cell (HUVEC)
apoptosis by anti-NP1-blocking peptide relative to a VEGF control
peptide are shown (Figure 3D), following analysis by flow
cytometry. RENCA cells were also treated with anti-NP1 and anti-
KDR-blocking peptides as previously described. These cells do not
express the VEGF receptors NP-1 or Flk-1. As expected, neither
peptide induced apoptosis of these tumour cells (data not shown),
demonstrating that the anti-NP1 and anti-KDR peptides only induce
apoptosis in NP-1-positive or KDR-positive cells, respectively.
To demonstrate that the induction of apoptosis in NP1-
expressing 4T1 and MDA cells by anti-NP1 peptide was not a
consequence of nonspecific cytotoxicity, RENCA cells, which do
not express the NP1 receptor, were treated with a scrambled
control peptide and the anti-NP1 peptide. As expected, neither
peptide induced apoptosis in NP1-negative RENCA cells.
Morphological evaluation of tumour cell apoptosis using
anti-NP1 and anti-KDR blocking peptides
To confirm the induction of 4T1 and MDA-MB-231 tumour cell
apoptosis using anti-NP1 blocking peptides, nuclear morphology
was examined by Hoechst 33342 staining. Tumour cells treated for
24 h with anti-NP1 blocking peptide (Figure 4C) demonstrated
typical apoptotic nuclei relative to untreated cells (Figure 4A) or
cells treated with a scrambled control peptide (Figure 4B). Anti-
KDR peptides however did not induce apoptosis of 4T1 and
MDA-MB-231 tumour cells (Figure 4D). These findings at the
morphological level are consistent with our findings using
Annexin V-FITC/PI by flow cytometry.
DISCUSSION
In contrast to the classical VEGF receptors, Flt-1 (VEGFR-1) and
Flk-1/KDR (VEGFR-2), and the mechanisms of VEGF signalling via
these tyrosine kinase receptors, relatively little is known regarding
the mechanisms governing VEGF signalling via the neuropilins.
A review of the literature of VEGF receptors and MDA-MB-231
tumour cells appears controversial, with a number of groups
reporting different VEGF receptor profiles. Soker et al (1998)
report that NP-1 is the only VEGF receptor associated with these
cells. This is consistent with the findings from Bachelder et al
(2001) who also failed to identify KDR expression by Western blot.
However, Tae-Hee et al (2003) found detectable levels of Flk-1/
KDR mRNA in MDA-MB-231 cells by Northern blot analysis. Such
findings are consistent with our observations using RT–PCR.
Despite a lack of evidence for Flt-1 expression at the protein level,
we detected Flt-1 mRNA (data not shown). This is in contrast to
that reported by Soker et al (1996) where they report undetectable
levels of Flt-1 mRNA. Similarly, there have been a number of
contrasting reports regarding NP-2 expression by MDA-MB-231
cells. Using 125I-VEGF145- and
125I-VEGF165-binding studies,
Gluzman-Poltorak et al (2000) deduced that MDA-MB-231 tumour
cells do not express detectable levels of functional NP-2 receptors.
Mamluk et al (2002) on the other hand report NP-2 expression on
these cells. Our findings that MDA-MB-231 cells and endothelial
cells express NP-2 at the protein level are in agreement with those
reported by the latter. We found that 4T1 tumour cells express
only NP-1 and Flt-1 receptors.
It has recently been reported that MDA-MB-231 breast
carcinoma cells express sema-3A and plexin-A1, which can both
bind to NP-1. Indeed Sema-3A and VEGF compete for binding to
NP-1. These act as antagonistic autocrine NP-1 ligands that
regulate breast carcinoma cell migration (Bachelder et al, 2003).
Plexin-A1 and plexin-A2 can form complexes with NP-1 and NP-2.
Having found NP-1 and NP-2 as the only VEGF receptors
expressed by these cells, we propose that VEGF signalling in
4T1  HUVEC
NP-1 
130 kDa
NP-2 
135 kDa
Murine Flt-1
175 kDa 
Human Flt-1
128 kDa 
HUVEC            MDA   
RENCA 
4T1 RENCA 
MDAA
B
Figure 1 Vascular endothelial growth factor receptor expression.
Tumour cells (4T1, MDA-MB-231, RENCA) and endothelial cells (HUVEC)
were cultured for 24 h, and VEGF receptor expression was anlaysed by
Western blot. 4T1, MDA-MB-231 and HUVEC cells expressed a 130 kDa
protein corresponding to the NP-1 receptor, while MDA-MB-231 and
HUVEC cells also expressed NP-2 as a 135 kDa protein (A). Flt-1 was
identified as a 175 kDa protein in murine 4T1 and RENCA cells and as a
128 kDa protein in endothelial cells (B).
Neuropilin-1 blockade induces tumour cell apoptosis
MP Barr et al
330
British Journal of Cancer (2005) 92(2), 328 – 333 & 2005 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
MDA-MB-231 cells may be mediated by plexin/NP complexes.
Since Bachelder et al demonstrated a role for such receptors in
tumour cell chemotaxis, these receptors may also play a functional
role in VEGF-mediated tumour cell survival. Since 4T1 tumour
cells only express NP-1 and Flt-1, both receptors may interact with
each other in order to transduce signalling via the classical tyrosine
kinase receptor, Flt-1. Alternatively, such signalling may be
mediated via plexin-A1. In endothelial cells (HUVEC), there exists
a number of possibilities whereby VEGF mediates signalling
through a number of its receptors. Evidence to date suggests that
VEGF signalling in endothelial cells occurs via the formation of
complexes involving KDR and NP-1. This in turn enhances the
binding of VEGF165 to KDR. Both KDR and NP-1 play an
important role in VEGF-mediated survival signalling as blockade
of either receptor induces apoptosis of endothelial cells.
In conclusion, we have demonstrated that a 24-mer peptide
targeting the VEGF165-binding site on the novel VEGF receptor,
NP-1, antagonises the autocrine antiapoptotic effects of VEGF on
Anti-KDR 
Anti-NP1 
4T1
Anti-NP1 
 MDA-MB-231
Anti-NP1 
Anti-KDR 
HUVEC 
 Anti-KDR 
A B
C
Figure 2 Anti-NP1 and anti-KDR peptide binding. Tumour and endothelial cells were incubated with 5-(6)-carboxyfluorescein-labelled anti-NP1 and
anti-KDR peptides on chamber slides for 18 h. Peptide binding to the VEGF receptors, NP-1 and KDR, was examined on 4T1 (A), MDA-MB-231 (B)
and HUVEC (C) cells by confocal microscopy ( 400 magnification). Images are representative of a scan zoom of between 1- and –4.2-fold.
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breast carcinoma cells. The use of peptides over monoclonal
antibodies offer a number of advantages including low manufac-
turing costs, lower risk of an immune response, improved organ
and tumour penetration and greater stability. Owing to their
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Figure 4 Hoechst staining of apoptotic tumour cells. 4T1 and MDA-MB-
231 tumour cells were incubated for 24 h with control peptide (B), anti-
NP1 (C) and anti-KDR (D) peptides. Following incubation, cells were
stained with Hoechst 33342 (1 mg ml1) in methanol and examined under
UV light ( 400 magnification). Treatment of 4T1 and MDA-MB-231
tumour cells with anti-NP1 peptides induced apoptosis, as seen by bright
fluorescing cells relative to control peptide and cells treated with anti-KDR
peptide.
Figure 3 Effect of anti-NP1 and anti-KDR peptides on tumour cell and
endothelial cell apoptosis. Murine 4T1 (A), human MDA-MB-231 (B)
tumour cells and HUVEC endothelial cells (C) were treated with anti-NP1
and anti-KDR peptides or a ‘scrambled’ control peptide for 24 h. Annexin V
binding to phosphatidylserine residues on the suface of apoptotic cells was
assessed by flow cytometry and the percentage apoptotic cells was
expressed relative to controls (mean7s.e.m) from three independent
experiments (*Po0.05 vs untreated cells, $Po0.05 vs control peptide).
Representative dot-plots demonstrating Annexin V-positive apoptotic cells
are shown in the lower right-hand quadrant following treatment of murine
4T1 tumour cells (top panel) and HUVECs (lower panel) with a scrambled
control peptide and anti-NP1 peptide (D).
Neuropilin-1 blockade induces tumour cell apoptosis
MP Barr et al
332
British Journal of Cancer (2005) 92(2), 328 – 333 & 2005 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
reduced size, peptides offer an attractive therapeutic option over
antibodies as inducers of apoptosis and angiogenesis inhibitors. As
chemo/radiotherapy increases VEGF expression (Gorski et al,
1999), an autocrine role for VEGF in protecting tumour cells from
apoptosis may explain the synergistic effect of VEGF blockade
when combined with chemo/radiotherapy (Harmey and Bouchier-
Hayes, 2002). Thus, it is likely that anti-NP1 peptides will be most
effective when used in combination with other antiangiogenic
strategies and traditional apoptosis-inducing chemotherapy/radio-
therapy regimens.
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